Journal Title：Pharmacology Research & Perspectives

PR&P is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. PR&P is a bi-monthly open access journal that publishes a range of article types, including: target validation (preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development); drug discovery reviews (strategy, hypotheses, and data resulting in a successful therapeutic drug); frontiers in translational medicine (drug and target validation for an unmet therapeutic need); pharmacological hypotheses (reviews that are oriented to inform a novel hypothesis); and replication studies (work that refutes key findings [failed replication] and work that validates key findings). PR&P publishes papers submitted directly to the journal and those referred from the journals of ASPET and the BPS

PR&P 由美國(guó)藥理學(xué)和實(shí)驗(yàn)治療學(xué)會(huì) (ASPET)、英國(guó)藥理學(xué)學(xué)會(huì) (BPS) 和 Wiley 聯(lián)合出版。PR&P 是一份雙月刊的開(kāi)放獲取期刊，出版各種類型的文章，包括：靶標(biāo)驗(yàn)證（表明假設(shè)不正確的臨床前論文或關(guān)于在早期臨床開(kāi)發(fā)中失敗的藥物的論文）；藥物發(fā)現(xiàn)評(píng)論（導(dǎo)致成功治療藥物的策略、假設(shè)和數(shù)據(jù)）；轉(zhuǎn)化醫(yī)學(xué)前沿（針對(duì)未滿足的治療需求的藥物和靶標(biāo)驗(yàn)證）；藥理學(xué)假設(shè)（旨在為新假設(shè)提供信息的評(píng)論）；以及復(fù)制研究（反駁關(guān)鍵發(fā)現(xiàn) [復(fù)制失敗] 的工作和驗(yàn)證關(guān)鍵發(fā)現(xiàn)的工作）。PR&P 發(fā)表直接提交給期刊的論文以及 ASPET 和 BPS 期刊推薦的論文

Pharmacology Research & Perspectives創(chuàng)刊于2013年，由Wiley-Blackwell出版商出版，收稿方向涵蓋General Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics全領(lǐng)域，此期刊水平偏中等偏靠后，在所屬細(xì)分領(lǐng)域中專業(yè)影響力一般，過(guò)審相對(duì)較易，如果您文章質(zhì)量佳，選擇此期刊，發(fā)表機(jī)率較高。平均審稿速度 20 Weeks ，影響因子指數(shù)2.9，該期刊近期沒(méi)有被列入國(guó)際期刊預(yù)警名單，廣大學(xué)者值得一試。